<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147197</url>
  </required_header>
  <id_info>
    <org_study_id>UL1309</org_study_id>
    <nct_id>NCT02147197</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      This study will evaluate the superiority of ulipristal acetate versus placebo for the
      treatment of abnormal uterine bleeding associated with uterine fibroids
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2014</start_date>
  <completion_date type="Actual">March 29, 2016</completion_date>
  <primary_completion_date type="Actual">March 29, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment</measure>
    <time_frame>Last 35 consecutive days on treatment in the 12-week Treatment Period</time_frame>
    <description>Participants recorded bleeding in a daily diary. Absence of bleeding was defined as no bleeding days (i.e. no entries for bleeding or heavy bleeding; however, spotting was allowed), during the last 35 consecutive days on treatment in the 12-week Treatment Period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Absence of Bleeding on Treatment</measure>
    <time_frame>From first dose up to the end of the 12-week Treatment Period</time_frame>
    <description>Time to absence of bleeding was defined as the duration in days from first dose to the first day in the time interval in which absence of bleeding occurs and persists through the last dose on treatment. The persistence of absence of bleeding occurred for a minimum of 35 consecutive days counting backward from the last dose on treatment in the 12-week Treatment Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absence of Bleeding From Day 11 Through the End of Treatment</measure>
    <time_frame>Day 11 through the end of the 12-week Treatment Period</time_frame>
    <description>Participants recorded bleeding in a daily diary. Absence of bleeding was defined as no bleeding days (i.e. no entries for bleeding or heavy bleeding; however, spotting was allowed), starting from Day 11 through the end of the 12-week Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL) Revised Activities Subscale Score at the End of Treatment Period</measure>
    <time_frame>Baseline (Day 1-4) to the end of 12-week Treatment Period</time_frame>
    <description>The UFS-QOL is a uterine fibroid-specific questionnaire consisting of 37 questions developed to evaluate symptoms of uterine fibroids and their impact on health-related quality of life in women with leiomyomas. The first 8 questions comprise the Symptom Severity subscale to assess symptoms experienced by women with uterine leiomyomas, the remaining 29 questions comprise 6 subscales (Concern, Activities, Energy/mood, Control, Self-consciousness, Sexual Function) which overall deal with women's feelings and experiences regarding impact of uterine leiomyoma symptoms on her life. Each item is scored between 1 and 5, where 1=none of the time or not at all and 5=all of the time or a very great deal. A Revised Activities subscale was created to include the most relevant items pertaining to physical and social activities with a total possible score of 0 to 100. Higher Revised Activities subscale scores indicate less impact on activities. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Leiomyoma</condition>
  <condition>Uterine Hemorrhage</condition>
  <arm_group>
    <arm_group_label>UPA 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UPA 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal acetate (UPA)</intervention_name>
    <description>UPA tablet</description>
    <arm_group_label>UPA 10 mg</arm_group_label>
    <arm_group_label>UPA 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablet.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>UPA 10 mg</arm_group_label>
    <arm_group_label>UPA 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal women, 18-50 years, inclusive.

          -  Cyclic abnormal uterine bleeding (heavy or prolonged).

          -  Menstrual blood loss (MBL) of â‰¥ 80 mL as measured by the alkaline hematin method in
             the first 8 days of menses.

          -  Minimum of one discrete leiomyoma observable by transvaginal ultrasound.

          -  Endometrial biopsy without evidence of malignancy or atypical or non-atypical
             hyperplasia

        Exclusion Criteria:

          -  History of uterine surgery that would interfere with the study endpoints.

          -  Known coagulation disorder including bleeding disorder or clotting disorder.

          -  History of, or current uterine, cervix, ovarian, or breast cancer.

          -  Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP),
             or total bilirubin two times or greater than the upper limit of normal rang
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females with abnormal uterine bleeding associated with leiomyomas were treated in this study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Chan</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Watson Investigational Site 125</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 102</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 112</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 115</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 116</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 114</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 106</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 122</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 130</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 105</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 104</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 120</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 103</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 123</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 111</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 124</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 131</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 129</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 132</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 110</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 113</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 121</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 109</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 107</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 119</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 108</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 101</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Investigational Site 126</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <results_first_submitted>March 15, 2019</results_first_submitted>
  <results_first_submitted_qc>March 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2019</results_first_posted>
  <disposition_first_submitted>March 16, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 16, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 20, 2017</disposition_first_posted>
  <last_update_submitted>April 19, 2019</last_update_submitted>
  <last_update_submitted_qc>April 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulipristal acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo tablet (5 mg and 10 mg), orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>UPA 5 mg</title>
          <description>Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>UPA 10 mg</title>
          <description>UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Miscellaneous Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population consisted of all randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching placebo tablet (5 mg and 10 mg), orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>UPA 5 mg</title>
          <description>UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>UPA 10 mg</title>
          <description>UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="5.1"/>
                    <measurement group_id="B2" value="40.5" spread="5.9"/>
                    <measurement group_id="B3" value="41.3" spread="5.1"/>
                    <measurement group_id="B4" value="41.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment</title>
        <description>Participants recorded bleeding in a daily diary. Absence of bleeding was defined as no bleeding days (i.e. no entries for bleeding or heavy bleeding; however, spotting was allowed), during the last 35 consecutive days on treatment in the 12-week Treatment Period.</description>
        <time_frame>Last 35 consecutive days on treatment in the 12-week Treatment Period</time_frame>
        <population>Intent-to-Treat (ITT) Population included all randomized participants. Data was summarized as per the treatment assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet (5 mg and 10 mg), orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UPA 5 mg</title>
            <description>UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>UPA 10 mg</title>
            <description>UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment</title>
          <description>Participants recorded bleeding in a daily diary. Absence of bleeding was defined as no bleeding days (i.e. no entries for bleeding or heavy bleeding; however, spotting was allowed), during the last 35 consecutive days on treatment in the 12-week Treatment Period.</description>
          <population>Intent-to-Treat (ITT) Population included all randomized participants. Data was summarized as per the treatment assigned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O2" value="47.2" lower_limit="31.6" upper_limit="63.2"/>
                    <measurement group_id="O3" value="58.3" lower_limit="41.2" upper_limit="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Absence of Bleeding on Treatment</title>
        <description>Time to absence of bleeding was defined as the duration in days from first dose to the first day in the time interval in which absence of bleeding occurs and persists through the last dose on treatment. The persistence of absence of bleeding occurred for a minimum of 35 consecutive days counting backward from the last dose on treatment in the 12-week Treatment Period.</description>
        <time_frame>From first dose up to the end of the 12-week Treatment Period</time_frame>
        <population>ITT Population included all randomized participants. Data was summarized as per the treatment assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet (5 mg and 10 mg), orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UPA 5 mg</title>
            <description>UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>UPA 10 mg</title>
            <description>UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Absence of Bleeding on Treatment</title>
          <description>Time to absence of bleeding was defined as the duration in days from first dose to the first day in the time interval in which absence of bleeding occurs and persists through the last dose on treatment. The persistence of absence of bleeding occurred for a minimum of 35 consecutive days counting backward from the last dose on treatment in the 12-week Treatment Period.</description>
          <population>ITT Population included all randomized participants. Data was summarized as per the treatment assigned.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The Median, upper and lower limit of 97.5% Confidence Interval were not estimated due to the low number of participants with events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="6.0" upper_limit="NA">The Median and upper limit of 97.5% Confidence Interval were not estimated due to the low number of participants with events.</measurement>
                    <measurement group_id="O3" value="9.5" lower_limit="5.0" upper_limit="NA">The upper limit of 97.5% Confidence Interval were not estimated due to the low number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Absence of Bleeding From Day 11 Through the End of Treatment</title>
        <description>Participants recorded bleeding in a daily diary. Absence of bleeding was defined as no bleeding days (i.e. no entries for bleeding or heavy bleeding; however, spotting was allowed), starting from Day 11 through the end of the 12-week Treatment Period.</description>
        <time_frame>Day 11 through the end of the 12-week Treatment Period</time_frame>
        <population>ITT Population included all randomized participants. Data was summarized as per the treatment assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet (5 mg and 10 mg), orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UPA 5 mg</title>
            <description>UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>UPA 10 mg</title>
            <description>UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Absence of Bleeding From Day 11 Through the End of Treatment</title>
          <description>Participants recorded bleeding in a daily diary. Absence of bleeding was defined as no bleeding days (i.e. no entries for bleeding or heavy bleeding; however, spotting was allowed), starting from Day 11 through the end of the 12-week Treatment Period.</description>
          <population>ITT Population included all randomized participants. Data was summarized as per the treatment assigned.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="43.4" lower_limit="28.2" upper_limit="59.6"/>
                    <measurement group_id="O3" value="58.3" lower_limit="41.2" upper_limit="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL) Revised Activities Subscale Score at the End of Treatment Period</title>
        <description>The UFS-QOL is a uterine fibroid-specific questionnaire consisting of 37 questions developed to evaluate symptoms of uterine fibroids and their impact on health-related quality of life in women with leiomyomas. The first 8 questions comprise the Symptom Severity subscale to assess symptoms experienced by women with uterine leiomyomas, the remaining 29 questions comprise 6 subscales (Concern, Activities, Energy/mood, Control, Self-consciousness, Sexual Function) which overall deal with women's feelings and experiences regarding impact of uterine leiomyoma symptoms on her life. Each item is scored between 1 and 5, where 1=none of the time or not at all and 5=all of the time or a very great deal. A Revised Activities subscale was created to include the most relevant items pertaining to physical and social activities with a total possible score of 0 to 100. Higher Revised Activities subscale scores indicate less impact on activities. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1-4) to the end of 12-week Treatment Period</time_frame>
        <population>Data was summarized as per treatment assigned and included all participants with data at both Baseline and Week 12. The Baseline row shows the actual scores. The results at Week 12 are the difference in scores from Baseline to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet (5 mg and 10 mg), orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UPA 5 mg</title>
            <description>UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>UPA 10 mg</title>
            <description>UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL) Revised Activities Subscale Score at the End of Treatment Period</title>
          <description>The UFS-QOL is a uterine fibroid-specific questionnaire consisting of 37 questions developed to evaluate symptoms of uterine fibroids and their impact on health-related quality of life in women with leiomyomas. The first 8 questions comprise the Symptom Severity subscale to assess symptoms experienced by women with uterine leiomyomas, the remaining 29 questions comprise 6 subscales (Concern, Activities, Energy/mood, Control, Self-consciousness, Sexual Function) which overall deal with women's feelings and experiences regarding impact of uterine leiomyoma symptoms on her life. Each item is scored between 1 and 5, where 1=none of the time or not at all and 5=all of the time or a very great deal. A Revised Activities subscale was created to include the most relevant items pertaining to physical and social activities with a total possible score of 0 to 100. Higher Revised Activities subscale scores indicate less impact on activities. A positive change from Baseline indicates improvement.</description>
          <population>Data was summarized as per treatment assigned and included all participants with data at both Baseline and Week 12. The Baseline row shows the actual scores. The results at Week 12 are the difference in scores from Baseline to Week 12.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.51" spread="26.41"/>
                    <measurement group_id="O2" value="29.60" spread="23.34"/>
                    <measurement group_id="O3" value="28.15" spread="23.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.26" spread="27.52"/>
                    <measurement group_id="O2" value="53.00" spread="34.36"/>
                    <measurement group_id="O3" value="61.04" spread="31.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study drug administration until the end of the 12-week off-treatment follow-up period (Up to 24 weeks)</time_frame>
      <desc>Safety Population consisted of all randomized participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching placebo tablet (5 mg and 10 mg), orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>UPA 5 mg</title>
          <description>UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>UPA 10 mg</title>
          <description>UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area, Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

